Masimo Receivables 2010-2025 | MASI

Masimo receivables for the quarter ending June 30, 2025 were $0.295B, a 12.53% decline year-over-year.

  • Masimo receivables for 2024 were $0.427B, a 19.97% increase from 2023.
  • Masimo receivables for 2023 were $0.356B, a 20.27% decline from 2022.
  • Masimo receivables for 2022 were $0.446B, a 122.06% increase from 2021.

Masimo Receivables 2010-2025 | MASI

  • Masimo receivables for 2024 were $0.427B, a 19.97% increase from 2023.
  • Masimo receivables for 2023 were $0.356B, a 20.27% decline from 2022.
  • Masimo receivables for 2022 were $0.446B, a 122.06% increase from 2021.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$184.3B
Intuitive Surgical (ISRG)$168.9B
IDEXX Laboratories (IDXX)$51.3B
Edwards Lifesciences (EW)$47.5B
Alcon (ALC)$40.1B
IQVIA Holdings (IQV)$32.1B
DexCom (DXCM)$30B
Mettler-Toledo (MTD)$26.5B
STERIS (STE)$24.5B
Waters (WAT)$17.5B
SONOVA HOLDING (SONVY)$17B
Hologic (HOLX)$14.8B
Penumbra (PEN)$10.4B
Globus Medical (GMED)$8.3B
Sysmex ADR (SSMXY)$8.1B
Teleflex (TFX)$5.7B
Glaukos (GKOS)$5.5B
TransMedics (TMDX)$4B
Integer Holdings (ITGR)$3.8B
LivaNova (LIVN)$3.1B
Alphatec Holdings (ATEC)$2.4B
PROCEPT BioRobotics (PRCT)$2.3B
Veracyte (VCYT)$2.3B
Artivion (AORT)$2.1B
Nihon Kohden (NHNKY)$1.9B
Elekta AB (EKTAY)$1.9B
Integra LifeSciences Holdings (IART)$1.2B
OPKO Health (OPK)$1.1B
Paragon 28 (FNA)$1.1B
Pulse Biosciences (PLSE)$1.1B